Aliskiren and HCTZ

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

High Blood Pressure

Conditions

High Blood Pressure

Trial Timeline

Feb 1, 2010 → Oct 1, 2011

About Aliskiren and HCTZ

Aliskiren and HCTZ is a approved stage product being developed by Novartis for High Blood Pressure. The current trial status is completed. This product is registered under clinical trial identifier NCT01056731. Target conditions include High Blood Pressure.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01056731ApprovedCompleted

Competing Products

20 competing products in High Blood Pressure

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Sepantronium BromideCothera BiosciencePhase 2
44
Edoxaban + ASADaiichi SankyoPhase 3
77
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
77
Bunazosin + Doxazosin + ValsartinEisaiApproved
85
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
77
Camrelizumab、Rivoceranib + CamrelizumabJiangsu Hengrui MedicinePhase 2
52
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
52
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
77
Mirvetuximab SoravtansineAbbViePhase 2
52
Zibotentan/Dapagliflozin + DapagliflozinAstraZenecaPhase 2
52
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tabletAstraZenecaPhase 1
33
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
77
Olaparib Pill + AZD6738AstraZenecaPhase 2
52
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
77